Authors' reply

摘要

We thank Lisa Grech and colleagues for their Correspondence concerning our Article on the MS-SMART trial. This multiarm phase 2b trial effectively condensed, into one well powered trial, the study of three re-purposed drugs with distinct mechanisms of action potentially relevant to slowing progression in secondary progressive multiple sclerosis. Despite positive experimental and early clinical work, unfortunately none of the drugs had any effect on slowing the rate of whole-brain atrophy (primary outcome), nor on a variety of secondary outcome measures.